James C. Yang
Impact in
- Immunology top 0.05%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Oncology top 0.02%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
Papers in
- Oncology 104
- CAR-T cell therapy research 75
- Cancer Immunotherapy and Biomarkers 41
- Immunology 88
- Immunotherapy and Immune Responses 78
- Immune Cell Function and Interaction 15
- T-cell and B-cell Immunology 14
- Co-authors
- Steven A. Rosenberg (74 shared papers)Nicholas P. Restifo (24 shared papers)Mark E. Dudley (20 shared papers)Richard A. Morgan (7 shared papers)Richard M. Sherry (40 shared papers)Carolyn M. Laurençot (5 shared papers)Mio Kitano (1 shared paper)John R. Wunderlich (14 shared papers)
- Journals
- Journal of Clinical Oncology (18 papers)Journal of Immunotherapy (17 papers)Clinical Cancer Research (8 papers)Journal for ImmunoTherapy of Cancer (7 papers)Blood (7 papers)
- Partner nations
- United StatesTaiwanSouth Korea
In The Last Decade
James C. Yang
134 papers receiving 20.4k citations
James C. Yang's Hit Papers
Peers
Comparison fields: 5 of 138
- Immunology 12.0k
- Oncology 15.3k
- Genetics 4.1k
- Biotechnology 1.2k
- Molecular Biology 5.7k
Countries citing papers authored by James C. Yang
This map shows the geographic impact of James C. Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James C. Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James C. Yang more than expected).
Fields of papers citing papers by James C. Yang
This network shows the impact of papers produced by James C. Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James C. Yang. The network helps show where James C. Yang may publish in the future.
Co-authors
The 25 scholars most cited alongside James C. Yang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 140 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Cancer immunotherapy: moving beyond current vaccines Hit paper breakdown → | 2004 | 2287 |
| 2 | Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2 Hit paper breakdown → | 2010 | 1939 |
| 3 | Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer Hit paper breakdown → | 2014 | 1278 |
| 4 | Adoptive cell transfer: a clinical path to effective cancer immunotherapy Hit paper breakdown → | 2008 | 1246 |
| 5 | B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells Hit paper breakdown → | 2011 | 1136 |
| 6 | A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer Hit paper breakdown → | 2006 | 984 |
| 7 | Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma Hit paper breakdown → | 2010 | 954 |
| 8 | Gene Transfer into Humans — Immunotherapy of Patients with Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene Transduction Hit paper breakdown → | 1990 | 898 |
| 9 | T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis Hit paper breakdown → | 2010 | 791 |
| 10 | Phase I Study of the Intravenous Administration of AttenuatedSalmonella typhimuriumto Patients With Metastatic Melanoma Hit paper breakdown → | 2002 | 565 |
| 11 | 1999 | 339 | |
| 12 | 2015 | 332 | |
| 13 | 2014 | 304 | |
| 14 | Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma Hit paper breakdown → | 2019 | 301 |
| 15 | 2019 | 285 | |
| 16 | 2001 | 279 | |
| 17 | 2002 | 274 | |
| 18 | 2004 | 260 | |
| 19 | 2010 | 245 | |
| 20 | In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. | 1995 | 226 |
About James C. Yang
James C. Yang is a scholar working on Oncology, Immunology, Molecular Biology, Genetics and Pulmonary and Respiratory Medicine, having authored 140 papers that have together received 20.9k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (78 papers), CAR-T cell therapy research (75 papers), Cancer Immunotherapy and Biomarkers (41 papers), Virus-based gene therapy research (22 papers), Immune Cell Function and Interaction (15 papers), vaccines and immunoinformatics approaches (15 papers), T-cell and B-cell Immunology (14 papers) and Monoclonal and Polyclonal Antibodies Research (11 papers). The work is most often cited by research in Immunology (12.0k citations), Oncology (15.3k citations), Genetics (4.1k citations), Biotechnology (1.2k citations) and Molecular Biology (5.7k citations). James C. Yang has collaborated with scholars based in United States, Taiwan and South Korea. Frequent co-authors include Steven A. Rosenberg, Nicholas P. Restifo, Mark E. Dudley, Richard A. Morgan, Richard M. Sherry, Carolyn M. Laurençot, Mio Kitano, John R. Wunderlich, Udai S. Kammula and Suzanne L. Topalian. Their work appears in journals such as Journal of Clinical Oncology, Journal of Immunotherapy, Clinical Cancer Research, Journal for ImmunoTherapy of Cancer and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.